弊社は、スウェーデンのHuman Protein Atlas（HPA） プロジェクトで開発・検証された抗体を販売するAtlas Antidodies社の製品について取扱を開始しました。
Atlas Antibodies appoint Nacalai Tesque, based in Kyoto, as distributor in Japan for its polyclonal and monoclonal antibody reagents
Press release Kyoto (Japan) and Stockholm (Sweden), December 1st 2012,
The 166 years old Japanese company Nacalai Tesque with HQ in Kyoto and 14 sales offices across the country was selected by Atlas Antibodies to directly distribute its polyclonal and monoclonal antibodies against human proteins for research purposes in Japan. Nacalai Tesque not only has a strong distribution net-work in both Kansai and Kanto areas, but also provides direct sales channels to end users.
We are excited about the collaboration with Atlas Antibodies. We believe the more than 14,000 primary antibodies and 700 Characterization data for each antibody originally developed and validated within the Human Protein Atlas (HPA) project will be valuable for Japanese researchers. Nacalai’s collaboration with Atlas Antibodies demonstrates our long-term commitment and continued leadership in introducing Atlas Antibodies’ highly characterized antibodies targeting human proteins to the Japanese scientific research community.” said Mr. Yoshinari Morisaki, Head of Marketing of Nacalai Tesque
“We are very glad to enter into this distribution and sales agreement with Nacalai Tesque in Japan. Their market knowledge and for Japan unique direct sales capability gives us great opportunities to increase sales reaching new market segments and customers for our polyclonal antibodies that are derived from the Human Protein Atlas (HPA) project, as well as our newly launched monoclonal antibodies. Nacalai Tesque’s long history creates added trust in the market and with modern tools like their e-commerce site also offers our products in new convenient ways to younger researchers”, says Dr Marianne Hansson, CEO of Atlas Antibodies. “We look forward to building a strong antibody reagents brand in Japan together with Nacalai Tesque”, she continues.
About Nacalai Tesque Inc.:
Nacalai Tesque, Inc. is a manufacturing and marketing company of research products with its principle of business and head office in Kyoto, Japan. The organization was established in 1846 selling traditional Japanese and Chinese medicines, and was formally incorporated as a research reagent company in 1958. Since then Nacalai Tesque has been delivering world class service in the field of scientific research around the world.
Nacalai Tesque also acts as a major distributor for foreign companies who desire to expand business into the Japanese Life Science market. Nacalai Tesque maintains 14 sales offices with over 120 direct sales representatives throughout Japan. To supplement these sales offices, Nacalai Tesque has a relationship with over 50 sub-distributors in Japan. Through its own sales offices, and with the use of sub-distributors, Nacalai Tesque is able to deliver first class service to all of Japan.
About Atlas Antibodies AB:
Atlas Antibodies is a Swedish biotech company founded in 2006 by researchers at the Royal Institute of Technology (KTH) in Stockholm and the Rudbeck Laboratory, Uppsala University in Uppsala. Atlas Antibodies is a spin out from the Swedish Human Protein Atlas (HPA) project and have the exclusive right to manufacture, market and sell the antibodies developed and characterized within the HPA project.
Atlas Antibodies’ research reagents catalogue currently consists of more than 14,000 primary polyclonal (rabbit) antibodies targeting human proteins. We are currently covering more than 60% of the human proteome. All products have been tested in a large variety of normal and cancer tissues by the HPA project, and the characterization data is freely available online via the HPA portal (www.proteinatlas.org). All of our antibodies have been fully validated for Immunohistochemistry (IHC), and there are 700 searchable IHC images available for each antibody in the public database. Furthermore many of the antibodies are also verified to Western Blot (WB) and Immunofluorescence (IF), as well as rodent material. Recently we also launched our own monoclonal antibodies (mouse) series.
For more information please see www.atlasantibodies.com
For Nacalai Tesque:
Mr. Takatoshi Nakarai,
+81 (75) 251 1723
firstname.lastname@example.org (Marketing Department)
For Atlas Antibodies:
Dr Marianne Hansson
Chief Executive Officer
+46 (8) 54 59 58 52